Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies
- PMID: 28548638
- PMCID: PMC5472438
- DOI: 10.7554/eLife.27389
Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies
Abstract
The HIV-1 envelope (Env) glycoprotein binds to host cell receptors to mediate membrane fusion. The prefusion Env trimer is stabilized by V1V2 loops that interact at the trimer apex. Broadly neutralizing antibodies (bNAbs) against V1V2 loops, exemplified by PG9, bind asymmetrically as a single Fab to the apex of the symmetric Env trimer using a protruding CDRH3 to penetrate the Env glycan shield. Here we characterized a distinct mode of V1V2 epitope recognition by the new bNAb BG1 in which two Fabs bind asymmetrically per Env trimer using a compact CDRH3. Comparisons between cryo-EM structures of Env trimer complexed with BG1 (6.2 Å resolution) and PG9 (11.5 Å resolution) revealed a new V1V2-targeting strategy by BG1. Analyses of the EM structures provided information relevant to vaccine design including molecular details for different modes of asymmetric recognition of Env trimer and a binding model for BG1 recognition of V1V2 involving glycan flexibility.
Keywords: Cryo-EM; Human; biophysics; broadly neutralizing antibodies; structural biology; virus.
Conflict of interest statement
MCN: Senior editor,
The other authors declare that no competing interests exist.
Figures














Similar articles
-
Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.Cell Rep. 2020 Apr 7;31(1):107488. doi: 10.1016/j.celrep.2020.03.052. Cell Rep. 2020. PMID: 32268107
-
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.Immunity. 2017 May 16;46(5):777-791.e10. doi: 10.1016/j.immuni.2017.04.011. Immunity. 2017. PMID: 28514685 Free PMC article.
-
Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.J Virol. 2015 Dec 30;90(6):2740-55. doi: 10.1128/JVI.02380-15. J Virol. 2015. PMID: 26719262 Free PMC article.
-
Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review.J Int AIDS Soc. 2021 Nov;24 Suppl 7(Suppl 7):e25797. doi: 10.1002/jia2.25797. J Int AIDS Soc. 2021. PMID: 34806305 Free PMC article. Review.
-
The HIV-1 envelope glycoprotein structure: nailing down a moving target.Immunol Rev. 2017 Jan;275(1):21-32. doi: 10.1111/imr.12507. Immunol Rev. 2017. PMID: 28133813 Free PMC article. Review.
Cited by
-
Mosaic quadrivalent influenza vaccine single nanoparticle characterization.Sci Rep. 2024 Feb 24;14(1):4534. doi: 10.1038/s41598-024-54876-2. Sci Rep. 2024. PMID: 38402303 Free PMC article.
-
Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions.Nat Commun. 2018 Oct 26;9(1):4489. doi: 10.1038/s41467-018-06794-x. Nat Commun. 2018. PMID: 30367034 Free PMC article.
-
V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.Vaccines (Basel). 2019 Aug 6;7(3):82. doi: 10.3390/vaccines7030082. Vaccines (Basel). 2019. PMID: 31390725 Free PMC article. Review.
-
Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies.Viruses. 2021 Jul 20;13(7):1405. doi: 10.3390/v13071405. Viruses. 2021. PMID: 34372611 Free PMC article. Review.
-
HIV-1 Envelope Conformation, Allostery, and Dynamics.Viruses. 2021 May 7;13(5):852. doi: 10.3390/v13050852. Viruses. 2021. PMID: 34067073 Free PMC article. Review.
References
-
- Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallographica Section D Biological Crystallography. 2010;66:213–221. doi: 10.1107/S0907444909052925. - DOI - PMC - PubMed
-
- Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503:224–228. doi: 10.1038/nature12744. - DOI - PMC - PubMed
-
- Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E, Marshall DJ, Crump JA, Kapiga SH, Sam NE, Sinangil F, Pancera M, Yongping Y, Zhang B, Zhu J, Kwong PD, O'Dell S, Mascola JR, Wu L, Nabel GJ, Phogat S, Seaman MS, Whitesides JF, Moody MA, Kelsoe G, Yang X, Sodroski J, Shaw GM, Montefiori DC, Kepler TB, Tomaras GD, Alam SM, Liao HX, Haynes BF. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology. 2011;85:9998–10009. doi: 10.1128/JVI.05045-11. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous